Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCOV COVID-19 Vaccine Booster in Adults
NCT05679466Phase 1Unknown
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ReCOV with ReCOV placebo (2 arms). Primary endpoints: Solicited Adverse Events at 7 days, Unsolicited Adverse Events at 30 days and 1 more. Status: unknown.
02
Drugs
ReCOV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05679466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679466.